|Bid||43.40 x 1800|
|Ask||43.72 x 1200|
|Day's Range||43.05 - 43.68|
|52 Week Range||32.99 - 46.29|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||307.80|
|Earnings Date||Oct 26, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.87|
The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.
In this article, we will discuss the top 10 new stocks for 2021 to buy now according to Qing Li’s Sciencast Management portfolio. If you want to skip our detailed analysis of Li’s history, investment philosophy, and hedge fund performance, go directly to the top 5 New Stocks for 2021: Qing Li’s Sciencast Management Portfolio. […]
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.